Cell-Free Synthesis Meets Antibody Production: A Review
Engineered antibodies are key players in therapy, diagnostics and research. In addition to full size immunoglobulin gamma (IgG) molecules, smaller formats of recombinant antibodies, such as single-chain variable fragments (scFv) and antigen binding fragments (Fab), have emerged as promising alternat...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2015-01-01
|
| Series: | Antibodies |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2073-4468/4/1/12 |
| _version_ | 1819266347097391104 |
|---|---|
| author | Marlitt Stech Stefan Kubick |
| author_facet | Marlitt Stech Stefan Kubick |
| author_sort | Marlitt Stech |
| collection | DOAJ |
| description | Engineered antibodies are key players in therapy, diagnostics and research. In addition to full size immunoglobulin gamma (IgG) molecules, smaller formats of recombinant antibodies, such as single-chain variable fragments (scFv) and antigen binding fragments (Fab), have emerged as promising alternatives since they possess different advantageous properties. Cell-based production technologies of antibodies and antibody fragments are well-established, allowing researchers to design and manufacture highly specific molecular recognition tools. However, as these technologies are accompanied by the drawbacks of being rather time-consuming and cost-intensive, efficient and powerful cell-free protein synthesis systems have been developed over the last decade as alternatives. So far, prokaryotic cell-free systems have been the focus of interest. Recently, eukaryotic in vitro translation systems have enriched the antibody production pipeline, as these systems are able to mimic the natural pathway of antibody synthesis in eukaryotic cells. This review aims to overview and summarize the advances made in the production of antibodies and antibody fragments in cell-free systems. |
| first_indexed | 2024-12-23T20:59:49Z |
| format | Article |
| id | doaj.art-493bf686bfbe4a548e7096b24327ddc3 |
| institution | Directory Open Access Journal |
| issn | 2073-4468 |
| language | English |
| last_indexed | 2024-12-23T20:59:49Z |
| publishDate | 2015-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibodies |
| spelling | doaj.art-493bf686bfbe4a548e7096b24327ddc32022-12-21T17:31:24ZengMDPI AGAntibodies2073-44682015-01-0141123310.3390/antib4010012antib4010012Cell-Free Synthesis Meets Antibody Production: A ReviewMarlitt Stech0Stefan Kubick1Fraunhofer Institute for Cell Therapy and Immunology (IZI), Branch Bioanalytics and Bioprocesses Potsdam-Golm (IZI-BB), Am Mühlenberg 13, 14476 Potsdam, GermanyFraunhofer Institute for Cell Therapy and Immunology (IZI), Branch Bioanalytics and Bioprocesses Potsdam-Golm (IZI-BB), Am Mühlenberg 13, 14476 Potsdam, GermanyEngineered antibodies are key players in therapy, diagnostics and research. In addition to full size immunoglobulin gamma (IgG) molecules, smaller formats of recombinant antibodies, such as single-chain variable fragments (scFv) and antigen binding fragments (Fab), have emerged as promising alternatives since they possess different advantageous properties. Cell-based production technologies of antibodies and antibody fragments are well-established, allowing researchers to design and manufacture highly specific molecular recognition tools. However, as these technologies are accompanied by the drawbacks of being rather time-consuming and cost-intensive, efficient and powerful cell-free protein synthesis systems have been developed over the last decade as alternatives. So far, prokaryotic cell-free systems have been the focus of interest. Recently, eukaryotic in vitro translation systems have enriched the antibody production pipeline, as these systems are able to mimic the natural pathway of antibody synthesis in eukaryotic cells. This review aims to overview and summarize the advances made in the production of antibodies and antibody fragments in cell-free systems.http://www.mdpi.com/2073-4468/4/1/12cell-freecell-free protein synthesisantibodyantibody fragmentscFvdisulfide bond formationmicrosomal vesicleseukaryotic lysate |
| spellingShingle | Marlitt Stech Stefan Kubick Cell-Free Synthesis Meets Antibody Production: A Review Antibodies cell-free cell-free protein synthesis antibody antibody fragment scFv disulfide bond formation microsomal vesicles eukaryotic lysate |
| title | Cell-Free Synthesis Meets Antibody Production: A Review |
| title_full | Cell-Free Synthesis Meets Antibody Production: A Review |
| title_fullStr | Cell-Free Synthesis Meets Antibody Production: A Review |
| title_full_unstemmed | Cell-Free Synthesis Meets Antibody Production: A Review |
| title_short | Cell-Free Synthesis Meets Antibody Production: A Review |
| title_sort | cell free synthesis meets antibody production a review |
| topic | cell-free cell-free protein synthesis antibody antibody fragment scFv disulfide bond formation microsomal vesicles eukaryotic lysate |
| url | http://www.mdpi.com/2073-4468/4/1/12 |
| work_keys_str_mv | AT marlittstech cellfreesynthesismeetsantibodyproductionareview AT stefankubick cellfreesynthesismeetsantibodyproductionareview |